Form 4: Actuate Therapeutics CFO Paul Lytle Reports Stock Option Grants
SEC Filing (Form 4)
Paul Lytle, CFO of Actuate Therapeutics, reports the acquisition of employee stock options.
Summary
- Paul Lytle, the Chief Financial Officer of Actuate Therapeutics, filed a Form 4 with the SEC.
- The report details the grant of two employee stock option tranches.
- The first tranche consists of options to purchase 49,394 shares at an exercise price of $6.70, vesting 25% on April 1, 2026, and the remaining 75% in equal monthly installments over the following 36 months.
- The second tranche consists of options to purchase 41,899 shares at an exercise price of $6.70, vesting 25% on August 14, 2025, and the remaining 75% in equal monthly installments over the following 36 months.
- Following these transactions, Lytle directly owns options to purchase 49,394 and 41,899 shares of Actuate Therapeutics stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.
Positives
- The grant of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedules and exercise prices are typically structured to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the option grants positively as they align management's interests with the company's long-term success.
- Employees may see the option grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction (grant of stock options) |
| 08/14/2025 | 25% of 41,899 options vest |
| 04/01/2026 | 25% of 49,394 options vest |
| 03/31/2035 | Expiration date of the options |
| 04/02/2025 | Date of Form 4 filing |
Keywords
Form 4, Stock Options, Beneficial Ownership, Actuate Therapeutics, Paul Lytle, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.